Respiratorius AB (publ) (HF00)
Market Closed
17 Jul, 20:00
XSTU XSTU Primary €
0. 23
-0.01
-4.1322%
€
2.47M Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 0.24
Previous Close Want to track HF00 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
HF00 closed yesterday lower at €0.23, a decrease of -4.1322% from Thursday's close, completing a monthly increase of 18.3673% or €0.04. Over the past 12 months, HF00 stock gained 87.8542%.
HF00 is not paying dividends to its shareholders.
Respiratorius AB (publ) has completed 1 stock splits, with the recent split occurring on Nov 27, 2024.
The company's stock is traded on one exchange.
Respiratorius AB (publ) (HF00) FAQ
What is the stock price today?
The current price is €0.23.
On which exchange is it traded?
Respiratorius AB (publ) is listed on XSTU.
What is its stock symbol?
The ticker symbol is HF00.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 2.47M.
Has Respiratorius AB (publ) ever had a stock split?
Respiratorius AB (publ) had 1 splits and the recent split was on Nov 27, 2024.
Respiratorius AB (publ) Profile
| Biotechnology Industry | Healthcare Sector | Mr. Johan Drott Ph.D. CEO | XSTU Exchange | - ISIN |
| Sweden Country | - Employees | - Last Dividend | 27 Nov 2024 Last Split | - IPO Date |
Overview
Respiratorius AB (publ) is a Swedish research-based company, established in 1998, with its operations rooted in the development of innovative drug candidates aimed at treating conditions like cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s dedication to tackling some of the most serious health challenges through advanced research and development positions it at the forefront of medical innovation in the pharmaceutical sector. Based in Lund, Sweden, Respiratorius AB is committed to advancing its pipeline of drug candidates to address unmet medical needs in these critical disease areas.
Products and Services
- VAL001 for Diffuse Large B-Cell Lymphoma (Completed Phase III Clinical Trials): This pioneering drug candidate developed by Respiratorius AB has successfully completed Phase III clinical trials. It is designed to treat diffuse large B-cell lymphoma, a type of cancer that affects the lymphatic system, demonstrating the company’s commitment to cancer research and its capability to bring novel treatments closer to market.
- VAL001 for Relapsing Diffuse Large B-Cell Lymphoma (Preclinical Phase): Building on the foundation laid by its initial indication, VAL001 is also being explored for its potential in treating relapsing diffuse large B-cell lymphoma. Currently in the preclinical phase, this expansion of its application underscores the versatility and broad therapeutic potential of the VAL001 drug candidate in the realm of oncology.
Contact Information
Address: Medicon Village
Phone: 46 7 09 22 41 40
Website: https://www.respiratorius.com
